Personalized Vitamin D Supplementation Reduces Heart Attack Risk by 52% in Clinical Trial
By
brandonb
Fresh out the oven, still warm. Top of the tray.
Summary
A new randomized controlled trial called TARGET-D presented at the American Heart Association Scientific Sessions found that personalized vitamin D supplementation, with dosages adjusted based on regular blood tests to maintain levels between 40-80 ng/mL, reduced heart attack risk by 52% in people who had previously experienced a heart attack. The study highlights the significance of this finding given that heart attacks are the leading cause of death globally and vitamin D deficiency affects about one billion people worldwide, with supplementation being an affordable intervention.
Key quotes
· 4 pulledA new study showed that Vitamin D is good for your heart, cutting heart attacks by 52%.
This is important since heart attacks are the #1 cause of death, about one billion people worldwide are deficient in Vitamin D, and supplementing vitamin D is cheap.
TARGET-D is a randomized trial in people with who previously had a heart attack, presented at American Heart Association (AHA) Scientific Sessions.
In the study, they measured vitamin D blood levels every 3 months, then adjusted dosage of a vitamin D3 supplement to keep blood levels within a target range of 40–80 ng/mL.
You might also wanna read
Clinical Trial Finds Coffee Consumption Reduces Recurrent Atrial Fibrillation Risk
A multicenter randomized clinical trial (DECAF) involving 200 patients with persistent atrial fibrillation (AF) undergoing cardioversion fou
jamanetwork.com·6mo ago
Study Links Long-Term Melatonin Use to Increased Heart Failure and Mortality Risks
A preliminary study presented at the American Heart Association's Scientific Sessions 2025 found that long-term melatonin use (one year or l
Study Reveals Myocardial Infarction May Be Caused by Bacterial Infections
A groundbreaking study by Finnish and UK researchers reveals that myocardial infarction (heart attack) may be an infectious disease, challen
tuni.fi·8mo ago
Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a
npr.org·6h ago
GeneSkin Develops mRNA Therapy Targeting Skin Stem Cells for Rejuvenation and Hair Growth
GeneSkin is developing a novel mRNA therapy targeting basal stem cells in the skin to address a wide range of dermatological issues includin
wyss.harvard.edu·9h ago
First human trial begins for drug that could regrow missing teeth
Kyoto University Hospital has launched the first human trial of TRG-035, a drug designed to regrow teeth in adults by blocking a protein tha
boingboing.net·1d ago